Clinical trials: Cancer of Pancreas
Urothelial Bladder Cancer, Triple-negative Breast Cancer
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
- Conditions
- Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02527434
- Testing
- Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Pancreatic Neoplasms
Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Determination of the maximum tolerated dose (MTD), safety, and tolerability when BI 2536 was given on Day 1 and Day 15 in combination with gemcitabine given on Day 1, Day 8 and Day 15 every 28 days in patients with locally…
- Trial name
- NCT02215044
- Testing
- BI 2536, intravenous, Gemcitabine, intravenous
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Pancreatic Cancer
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated…
- Trial name
- NCT02047500
- Testing
- TH-302, Nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- ImmunoGenesis
Pancreatic Cancer
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499265
- Testing
- gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671
- Where
- 39 sites in Germany, Hungary and 4 more
- Volunteers
- 95 people
- Sponsor
- Heidelberg Pharma AG
Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC)
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
- Trial name
- NCT07699757
- Testing
- HSK41959, Sintilimab, Pemetrexed + Cisplatin /Carboplatin
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
The aim of this adaptive Phase 3 trial is to show a statistically significant superiority of EndoTAG-1 in combination with gemcitabine compared to gemcitabine monotherapy in patients with locally advanced/metastatic pancreatic…
- Conditions
- Metastatic Pancreas Cancer, Locally Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT03126435
- Testing
- EndoTAG-1, Gemcitabine
- Where
- 68 sites in United States, France and 5 more
- Volunteers
- 218 people
- Sponsor
- SynCore Biotechnology Co., Ltd.
Advanced Pancreatic Cancer
A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
The goal of this clinical trial is to assess the efficacy and safety of Pimicotinib (ABSK021) in combination with chemotherapy with or without Toripalimab in patients with advanced pancreatic cancer.
- Trial name
- NCT06111274
- Testing
- Pimicotinib (ABSK021)
- Where
- 5 sites in China
- Volunteers
- 82 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Pain Management, Cancer Pain
A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain
The purpose of this study is to compare efficacy of pain treatment with ITDD to efficacy of pain treatment with CMM in patients with pancreatic cancer pain.
- Trial name
- NCT02578459
- Testing
- Intrathecal Drug Delivery System, Conventional Medical Management
- Where
- United States
- Sponsor
- Flowonix Medical
Pancreatic Cancer
Study of M2ES in Patients With Advanced Pancreatic Cancer After Gemcitabine Treatment Failure
The purpose of this study is to evaluate the safety and tolerability and determine the recommended dosing for the treatment in patients with advanced pancreatic cancer after fist-line Gemcitabine treatment failure.
- Trial name
- NCT01219192
- Testing
- M2ES, M2ES 60mg
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Beijing Protgen Biotechnology Development Co., Ltd.
Pancreatic Neuroendocrine Tumors (pNET)
BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.
This is a Phase II study in 2 stages, evaluating BEZ235 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy.
- Trial name
- NCT01658436
- Testing
- BEZ235 (Stage 1)
- Where
- 17 sites in United States, Austria and 7 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Pancreas Adenocarcinoma
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic…
- Trial name
- FABLOx (NCT02620800)
- Testing
- 5FU, nab-paclitaxel, bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Pancreatic Cancer
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
This open-label, single-arm, multicenter trial is designed to evaluate the safety of erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants with locally advanced, unresectable, or metastatic…
- Trial name
- NCT02694536
- Testing
- Erlotinib, Gemcitabine
- Where
- 11 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors.
- Trial name
- NCT02485119
- Testing
- BAY94-9343
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH
Metastatic Pancreatic Cancer
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
People with primary metastatic pancreatic cancer will be treated with nab-paclitaxel and gemcitabine in combination with an investigational agent called necuparanib (M402).
- Trial name
- NCT01621243
- Testing
- nab-paclitaxel, gemcitabine, Necuparanib
- Where
- 37 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Momenta Pharmaceuticals, Inc.
Advanced Solid Tumors
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer…
- Trial name
- NCT06544655
- Testing
- BMS-986484, Nivolumab, Oxaliplatin
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 213 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Pancreatic Cancer
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
The objectives of this multi-center, randomized, controlled trial are to evaluate the safety and efficacy of PANVAC-VF in combination with Granulocyte-macrophage colony-stimulating factor (GM-CSF) versus best supportive care or…
- Trial name
- NCT00088660
- Testing
- PANVAC™-VF
- Where
- 62 sites in United States
- Volunteers
- 250 people
- Sponsor
- Therion Biologics Corporation
Colorectal Cancer, Gastric Cancer
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A*0201 positive…
- Conditions
- Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT05360680
- Testing
- CUE-102
- Where
- 15 sites in United States
- Volunteers
- 42 people
- Sponsor
- Cue Biopharma
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.